{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:04:45Z","timestamp":1771603485523,"version":"3.50.1"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01749-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:14:00Z","timestamp":1771596840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRCA1-Associated Protein 1 (BAP1) in Human Cancer and its Emerging Role as a Novel Potential Therapeutic Target"],"prefix":"10.1007","volume":"28","author":[{"given":"Luigi","family":"Liguori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Polcaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Pagliara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ventin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Camillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Quattrocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoyang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Tejeda-Polanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina R","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1749_CR1","doi-asserted-by":"publisher","unstructured":"Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16:1097\u2013112. https:\/\/doi.org\/10.1038\/sj.onc.1201861","DOI":"10.1038\/sj.onc.1201861"},{"key":"1749_CR2","doi-asserted-by":"publisher","unstructured":"Jensen DE, Rauscher FJ. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci. 1999;886:191\u20134. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb09414.x","DOI":"10.1111\/j.1749-6632.1999.tb09414.x"},{"key":"1749_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.celrep.2016.05.096","volume":"16","author":"JM Baughman","year":"2016","unstructured":"Baughman JM, Rose CM, Kolumam G, Webster JD, Wilkerson EM, Merrill AE, et al. NeuCode Proteomics Reveals Bap1 Regulation of Metabolism. Cell Rep. 2016;16:583\u201395. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.096","journal-title":"Cell Rep"},{"key":"1749_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2\u2009+\u2009flux to mitochondria suppressing cell transformation. Nature. 2017;546:549\u201353. https:\/\/doi.org\/10.1038\/nature22798","journal-title":"Nature"},{"key":"1749_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","volume":"60","author":"ZM Eletr","year":"2011","unstructured":"Eletr ZM, Wilkinson KD. An emerging model for BAP1\u2019s role in regulating cell cycle progression. Cell Biochem Biophys. 2011;60:3\u201311. https:\/\/doi.org\/10.1007\/s12013-011-9184-6","journal-title":"Cell Biochem Biophys"},{"key":"1749_CR6","doi-asserted-by":"publisher","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","volume":"284","author":"YJ Machida","year":"2009","unstructured":"Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1. J Biol Chem. 2009;284:34179\u201388. https:\/\/doi.org\/10.1074\/jbc.M109.046755","journal-title":"J Biol Chem"},{"key":"1749_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cmet.2012.07.006","volume":"16","author":"H-B Ruan","year":"2012","unstructured":"Ruan H-B, Han X, Li M-D, Singh JP, Qian K, Azarhoush S, et al. O-GlcNAc transferase\/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1\u03b1 stability. Cell Metab. 2012;16:226\u201337. https:\/\/doi.org\/10.1016\/j.cmet.2012.07.006","journal-title":"Cell Metab"},{"key":"1749_CR8","doi-asserted-by":"publisher","unstructured":"Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111:285\u201390. https:\/\/doi.org\/10.1073\/pnas.1309085110","DOI":"10.1073\/pnas.1309085110"},{"key":"1749_CR9","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2017.95","volume":"24","author":"A Bononi","year":"2017","unstructured":"Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 2017;24:1694\u2013704. https:\/\/doi.org\/10.1038\/cdd.2017.95","journal-title":"Cell Death Differ"},{"key":"1749_CR10","unstructured":"Mb NP. Dec D, T P. BRCA1- and BRCA2- associated hereditary breast and ovarian cancer [Internet]. PubMed. 1993 [cited 2022 Dec 3]. . Accessed 3 2022."},{"key":"1749_CR11","doi-asserted-by":"publisher","unstructured":"Wu H, Wu X, Liang Z. Impact of germline and somatic BRCA1\/2 mutations: tumor spectrum and detection platforms. Gene Ther. 2017;24:601\u20139. https:\/\/doi.org\/10.1038\/gt.2017.73","DOI":"10.1038\/gt.2017.73"},{"key":"1749_CR12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2217\/fon-2018-0915","volume":"15","author":"V Di Nunno","year":"2019","unstructured":"Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, et al. BAP1 in solid tumors. Future Oncol. 2019;15:2151\u201362. https:\/\/doi.org\/10.2217\/fon-2018-0915","journal-title":"Future Oncol"},{"key":"1749_CR13","doi-asserted-by":"publisher","unstructured":"Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116\u201326. https:\/\/doi.org\/10.1097\/PAT.0b013e32835d0efb","DOI":"10.1097\/PAT.0b013e32835d0efb"},{"key":"1749_CR14","doi-asserted-by":"publisher","first-page":"567289","DOI":"10.3389\/fonc.2020.567289","volume":"10","author":"F Sabbatino","year":"2020","unstructured":"Sabbatino F, Liguori L, Malapelle U, Schiavi F, Tortora V, Conti V, et al. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. Front Oncol. 2020;10:567289. https:\/\/doi.org\/10.3389\/fonc.2020.567289","journal-title":"Front Oncol"},{"key":"1749_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pe\u00f1a-Llopis","year":"2012","unstructured":"Pe\u00f1a-Llopis S, Vega-Rub\u00edn-de-Celis S, Liao A, Leng N, Pav\u00eda-Jim\u00e9nez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751\u20139. https:\/\/doi.org\/10.1038\/ng.2323","journal-title":"Nat Genet"},{"key":"1749_CR16","doi-asserted-by":"publisher","unstructured":"Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470\u20133. https:\/\/doi.org\/10.1038\/ng.2813","DOI":"10.1038\/ng.2813"},{"key":"1749_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ng.956","volume":"43","author":"AM Goldstein","year":"2011","unstructured":"Goldstein AM. Germline BAP1 mutations and tumor susceptibility. Nat Genet. 2011;43:925\u20136. https:\/\/doi.org\/10.1038\/ng.956","journal-title":"Nat Genet"},{"key":"1749_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On W, Nairism\u00e4gi M-L, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474\u20138. https:\/\/doi.org\/10.1038\/ng.2806","journal-title":"Nat Genet"},{"key":"1749_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R De Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316. https:\/\/doi.org\/10.1038\/ng.3520","journal-title":"Nat Genet"},{"key":"1749_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372. https:\/\/doi.org\/10.1038\/ng.855","journal-title":"Nat Genet"},{"key":"1749_CR21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","volume":"11","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, Nilsson LM, Mitra S, Als\u00e9n S, Shelke GV, Sah VR, et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun. 2020;11:1894. https:\/\/doi.org\/10.1038\/s41467-020-15606-0","journal-title":"Nat Commun"},{"key":"1749_CR22","doi-asserted-by":"publisher","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","volume":"11","author":"M Carbone","year":"2015","unstructured":"Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet. 2015;11:e1005633. https:\/\/doi.org\/10.1371\/journal.pgen.1005633","journal-title":"PLoS Genet"},{"key":"1749_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153\u20139. https:\/\/doi.org\/10.1038\/nrc3459","journal-title":"Nat Rev Cancer"},{"key":"1749_CR24","doi-asserted-by":"publisher","unstructured":"M C, J T, K S, E S, Ls P, M L, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer genetics [Internet]. Cancer Genet; 2013 [cited 2022 Feb 7];206. https:\/\/doi.org\/10.1016\/j.cancergen.2013.05.018","DOI":"10.1016\/j.cancergen.2013.05.018"},{"key":"1749_CR25","unstructured":"R P, M C, C C, M A-R. BAP1 Tumor predisposition syndrome [Internet]. PubMed. 1993 [cited 2022 Feb 7]. https:\/\/pubmed.ncbi.nlm.nih.gov\/27748099\/. Accessed 7 Feb 2022"},{"key":"1749_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","volume":"48","author":"MH Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856\u20139. https:\/\/doi.org\/10.1136\/jmedgenet-2011-100156","journal-title":"J Med Genet"},{"key":"1749_CR27","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","volume":"9","author":"DA \\Kobrinski","year":"2020","unstructured":"\\Kobrinski DA, Yang H, Kittaneh M. BAP1: role in carcinogenesis and clinical implications. Translational Lung Cancer Res AME Publications. 2020;9:S60. https:\/\/doi.org\/10.21037\/tlcr.2019.11.24","journal-title":"Translational Lung Cancer Res AME Publications"},{"key":"1749_CR28","doi-asserted-by":"publisher","unstructured":"F S, F G, O B, M S, Sp C, M G, et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. European journal of cancer (Oxford, England: 1990) [Internet]. Eur J Cancer. 2021;149. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.035","DOI":"10.1016\/j.ejca.2021.02.035"},{"key":"1749_CR29","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064\u20138. https:\/\/doi.org\/10.1126\/science.278.5340.1064","journal-title":"Science"},{"key":"1749_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387\u201393. https:\/\/doi.org\/10.1016\/j.molonc.2011.07.001","journal-title":"Mol Oncol"},{"key":"1749_CR31","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms23158412","volume":"23","author":"D Kim","year":"2022","unstructured":"Kim D, Nam HJ. PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. Int J Mol Sci. 2022;23:8412. https:\/\/doi.org\/10.3390\/ijms23158412","journal-title":"Int J Mol Sci"},{"key":"1749_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2021.02.035","volume":"149","author":"F Schettini","year":"2021","unstructured":"Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. Eur J Cancer. 2021;149:134\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.035","journal-title":"Eur J Cancer"},{"key":"1749_CR33","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102091","journal-title":"Cancer Treat Rev"},{"key":"1749_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon J, Lee D, Lee S-A. BAP1 as a guardian of genome stability: implications in human cancer. Exp Mol Med Nat Publishing Group. 2023;55:745\u201354. https:\/\/doi.org\/10.1038\/s12276-023-00979-1","journal-title":"Exp Mol Med Nat Publishing Group"},{"key":"1749_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC de Scheuermann","year":"2010","unstructured":"Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. Nat Publishing Group. 2010;465:243\u20137. https:\/\/doi.org\/10.1038\/nature08966","journal-title":"Nat Publishing Group"},{"key":"1749_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1074\/jbc.M114.609834","volume":"290","author":"Y Okino","year":"2015","unstructured":"Okino Y, Machida Y, Frankland-Searby S, Machida YJ. BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes. J Biol Chem. 2015;290:1580\u201391. https:\/\/doi.org\/10.1074\/jbc.M114.609834","journal-title":"J Biol Chem"},{"key":"1749_CR37","doi-asserted-by":"publisher","unstructured":"Masclef L, Ahmed O, Estavoyer B, Larriv\u00e9e B, Labrecque N, Nijnik A, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ Nat Publishing Group. 2021;28:606\u201325. https:\/\/doi.org\/10.1038\/s41418-020-00709-4","DOI":"10.1038\/s41418-020-00709-4"},{"key":"1749_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cell.2009.04.042","volume":"138","author":"ME Sowa","year":"2009","unstructured":"Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138:389\u2013403. https:\/\/doi.org\/10.1016\/j.cell.2009.04.042","journal-title":"Cell"},{"key":"1749_CR39","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1128\/MCB.01517-08","volume":"29","author":"S Misaghi","year":"2009","unstructured":"Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol. 2009;29:2181\u201392. https:\/\/doi.org\/10.1128\/MCB.01517-08","journal-title":"Mol Cell Biol"},{"key":"1749_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","volume":"54","author":"N Mashtalir","year":"2014","unstructured":"Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell. 2014;54:392\u2013406. https:\/\/doi.org\/10.1016\/j.molcel.2014.03.002","journal-title":"Mol Cell"},{"key":"1749_CR41","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1128\/MCB.00396-10","volume":"30","author":"H Yu","year":"2010","unstructured":"Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and Is a critical regulator of gene expression. Mol Cell Biol. 2010;30:5071\u201385. https:\/\/doi.org\/10.1128\/MCB.00396-10","journal-title":"Mol Cell Biol"},{"key":"1749_CR42","doi-asserted-by":"publisher","unstructured":"Daou S, Barbour H, Ahmed O, Masclef L, Baril C, Sen Nkwe N, et al. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nat Commun Nat Publishing Group. 2018;9:4385. https:\/\/doi.org\/10.1038\/s41467-018-06854-2","DOI":"10.1038\/s41467-018-06854-2"},{"key":"1749_CR43","doi-asserted-by":"publisher","first-page":"28643","DOI":"10.1074\/jbc.M115.661553","volume":"290","author":"S Daou","year":"2015","unstructured":"Daou S, Hammond-Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono NVG, et al. The BAP1\/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer. J Biol Chem. 2015;290:28643\u201363. https:\/\/doi.org\/10.1074\/jbc.M115.661553","journal-title":"J Biol Chem"},{"key":"1749_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019","journal-title":"Mol Cell"},{"key":"1749_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.01.017","volume-title":"Regulation of DNA damage responses by ubiquitin and SUMO. Molecular cell [Internet]","author":"J Sp","year":"2013","unstructured":"Sp J. D D. Regulation of DNA damage responses by ubiquitin and SUMO. Molecular cell [Internet]. Mol Cell; 2013;49. https:\/\/doi.org\/10.1016\/j.molcel.2013.01.017"},{"key":"1749_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tcb.2009.03.001","volume":"19","author":"H van Attikum","year":"2009","unstructured":"van Attikum H, Gasser SM. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol. 2009;19:207\u201317. https:\/\/doi.org\/10.1016\/j.tcb.2009.03.001","journal-title":"Trends Cell Biol"},{"key":"1749_CR47","doi-asserted-by":"publisher","unstructured":"Se GS. P, G A. Prime, repair, restore: the active role of chromatin in the DNA damage response. Molecular cell [Internet]. Mol Cell. 2012;46. https:\/\/doi.org\/10.1016\/j.molcel.2012.06.002","DOI":"10.1016\/j.molcel.2012.06.002"},{"key":"1749_CR48","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1038\/sj.onc.1206176","volume":"21","author":"M Jasin","year":"2002","unstructured":"Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21:8981\u201393. https:\/\/doi.org\/10.1038\/sj.onc.1206176","journal-title":"Oncogene"},{"key":"1749_CR49","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","volume":"82","author":"TK Foo","year":"2022","unstructured":"Foo TK, Xia B. BRCA1-Dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Res. 2022;82:3191\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1535","journal-title":"Cancer Res"},{"key":"1749_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","volume":"69","author":"H Nishikawa","year":"2009","unstructured":"Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity. Cancer Res. 2009;69:111\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3355","journal-title":"Cancer Res"},{"key":"1749_CR51","doi-asserted-by":"publisher","unstructured":"T F, T T. T K, H N, T O. Functional link between BRCA1 and BAP1 through histone H2A, heterochromatin and DNA damage response. Current cancer drug targets [Internet]. Curr Cancer Drug Targets; 2016;16. https:\/\/doi.org\/10.2174\/1568009615666151030102427","DOI":"10.2174\/1568009615666151030102427"},{"key":"1749_CR52","doi-asserted-by":"publisher","unstructured":"Ismail IH, Davidson R, Gagn\u00e9 J-P, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014;74:4282\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3109","DOI":"10.1158\/0008-5472.CAN-13-3109"},{"key":"1749_CR53","doi-asserted-by":"publisher","unstructured":"W Z, Jb S, X FL, Dg C, C M. JM, BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nat. 2017;550. https:\/\/doi.org\/10.1038\/nature24060","DOI":"10.1038\/nature24060"},{"key":"1749_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao W, Steinfeld JB, Liang F, Chen X, Maranon DG, Ma CJ, et al. Promotion of RAD51-mediated homologous DNA pairing by BRCA1-BARD1. Nature. 2017;550:360\u20135. https:\/\/doi.org\/10.1038\/nature24060","journal-title":"Nature"},{"key":"1749_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","volume":"77","author":"J San Filippo","year":"2008","unstructured":"San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229\u201357. https:\/\/doi.org\/10.1146\/annurev.biochem.77.061306.125255","journal-title":"Annu Rev Biochem"},{"key":"1749_CR56","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41418-022-01024-w","volume":"29","author":"S-A Lee","year":"2022","unstructured":"Lee S-A, Lee D, Kang M, Kim S, Kwon S-J, Lee H-S, et al. BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability. Cell Death Differ. 2022;29:2381\u201398. https:\/\/doi.org\/10.1038\/s41418-022-01024-w","journal-title":"Cell Death Differ"},{"key":"1749_CR57","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1038\/ncomms6128","volume":"5","author":"H-S Lee","year":"2014","unstructured":"Lee H-S, Lee S-A, Hur S-K, Seo J-W, Kwon J. Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun. 2014;5:5128. https:\/\/doi.org\/10.1038\/ncomms6128","journal-title":"Nat Commun"},{"key":"1749_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.tcb.2014.06.004","volume":"24","author":"CB Gerhold","year":"2014","unstructured":"Gerhold CB, Gasser SM. INO80 and SWR complexes: relating structure to function in chromatin remodeling. Trends Cell Biol. 2014;24:619\u201331. https:\/\/doi.org\/10.1016\/j.tcb.2014.06.004","journal-title":"Trends Cell Biol"},{"key":"1749_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1101\/sqb.2010.75.063","volume":"75","author":"S Watanabe","year":"2010","unstructured":"Watanabe S, Peterson CL. The INO80 family of chromatin-remodeling enzymes: regulators of histone variant dynamics. Cold Spring Harb Symp Quant Biol. 2010;75:35\u201342. https:\/\/doi.org\/10.1101\/sqb.2010.75.063","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1749_CR60","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1038\/emboj.2009.258","volume":"28","author":"S Tyagi","year":"2009","unstructured":"Tyagi S, Herr W. E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J. 2009;28:3185\u201395. https:\/\/doi.org\/10.1038\/emboj.2009.258","journal-title":"EMBO J"},{"key":"1749_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.05.030","volume-title":"E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Molecular cell [Internet]","author":"ST Al","year":"2007","unstructured":"Al ST. C, J W, W H. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Molecular cell [Internet]. Mol Cell. 2007;27. https:\/\/doi.org\/10.1016\/j.molcel.2007.05.030"},{"key":"1749_CR62","doi-asserted-by":"publisher","unstructured":"Xx C, Jw YY. C, A H, B H, X Z, BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways. Cell death & disease [Internet]. Cell Death Dis. 2018;9. https:\/\/doi.org\/10.1038\/s41419-018-1087-7","DOI":"10.1038\/s41419-018-1087-7"},{"key":"1749_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/1878-0261.12844","volume":"15","author":"R Deng","year":"2021","unstructured":"Deng R, Guo Y, Li L, He J, Qiang Z, Zhang H, et al. BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN. Mol Oncol. 2021;15:279\u201398. https:\/\/doi.org\/10.1002\/1878-0261.12844","journal-title":"Mol Oncol"},{"key":"1749_CR64","doi-asserted-by":"publisher","unstructured":"Hj L, Mt TP, Ag CDB. C, R N, The tumor suppressor BAP1 regulates the hippo pathway in pancreatic ductal adenocarcinoma. Cancer Res. 2020;80. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1704","DOI":"10.1158\/0008-5472.CAN-19-1704"},{"key":"1749_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-0500-6","volume":"9","author":"W Sime","year":"2018","unstructured":"Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, K\u00f8hler JB, et al. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. Cell Death Dis. 2018;9:1\u201316. https:\/\/doi.org\/10.1038\/s41419-018-0500-6","journal-title":"Cell Death Dis"},{"key":"1749_CR66","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol Nat. 2018;20:1181\u201392. https:\/\/doi.org\/10.1038\/s41556-018-0178-0","journal-title":"Nat Cell Biol Nat Publishing Group"},{"key":"1749_CR67","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"key":"1749_CR68","doi-asserted-by":"publisher","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379. https:\/\/doi.org\/10.1038\/cdd.2015.158","DOI":"10.1038\/cdd.2015.158"},{"key":"1749_CR69","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195\u2013209. https:\/\/doi.org\/10.1007\/s00018-016-2194-1","journal-title":"Cell Mol Life Sci"},{"key":"1749_CR70","doi-asserted-by":"publisher","unstructured":"Yang WS, Stockwell BR, Ferroptosis. Death by Lipid Peroxidation. Trends Cell Biol. 2016;26:165\u201376. https:\/\/doi.org\/10.1016\/j.tcb.2015.10.014","DOI":"10.1016\/j.tcb.2015.10.014"},{"key":"1749_CR71","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, Redox Biology, and Disease. Cell. 2017;171:273\u201385. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021","journal-title":"Cell"},{"key":"1749_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","volume":"11","author":"R Shrestha","year":"2019","unstructured":"Shrestha R, Nabavi N, Lin Y-Y, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019;11:8. https:\/\/doi.org\/10.1186\/s13073-019-0620-3","journal-title":"Genome Med"},{"key":"1749_CR73","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers11081102","volume":"11","author":"Z van Souri","year":"2019","unstructured":"Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, et al. Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma. Cancers (Basel). 2019;11:1102. https:\/\/doi.org\/10.3390\/cancers11081102","journal-title":"Cancers (Basel)"},{"key":"1749_CR74","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","volume":"66","author":"G van Gezgin","year":"2017","unstructured":"Gezgin G, Dogrus\u00f6z M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, et al. Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. Cancer Immunol Immunother. 2017;66:903\u201312. https:\/\/doi.org\/10.1007\/s00262-017-1991-1","journal-title":"Cancer Immunol Immunother"},{"key":"1749_CR75","doi-asserted-by":"publisher","unstructured":"Figueiredo CR, Kalirai H, Sacco JJ, Azevedo RA, Duckworth A, Slupsky JR, et al. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. J Pathol. 2020;250:420\u201339. https:\/\/doi.org\/10.1002\/path.5384","DOI":"10.1002\/path.5384"},{"key":"1749_CR76","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3390\/cancers14153678","volume":"14","author":"CJ Kaler","year":"2022","unstructured":"Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez MI, Decatur CL, et al. BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas. Cancers (Basel). 2022;14:3678. https:\/\/doi.org\/10.3390\/cancers14153678","journal-title":"Cancers (Basel)"},{"key":"1749_CR77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","volume":"11","author":"M Ladanyi","year":"2019","unstructured":"Ladanyi M, Sanchez Vega F, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 2019;11:18. https:\/\/doi.org\/10.1186\/s13073-019-0631-0","journal-title":"Genome Med"},{"key":"1749_CR78","doi-asserted-by":"publisher","unstructured":"Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133. https:\/\/doi.org\/10.1126\/science.1194472","DOI":"10.1126\/science.1194472"},{"key":"1749_CR79","doi-asserted-by":"publisher","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135. https:\/\/doi.org\/10.1038\/ng.912","DOI":"10.1038\/ng.912"},{"key":"1749_CR80","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43:1018\u201321. https:\/\/doi.org\/10.1038\/ng.910","journal-title":"Nat Genet"},{"key":"1749_CR81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cge.12630","volume":"89","author":"K Rai","year":"2016","unstructured":"Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89:285\u201394. https:\/\/doi.org\/10.1111\/cge.12630","journal-title":"Clin Genet"},{"key":"1749_CR82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-015-0040-5","volume":"3","author":"S Klebe","year":"2015","unstructured":"Klebe S, Driml J, Nasu M, Pastorino S, Zangiabadi A, Henderson D, et al. BAP1 hereditary cancer predisposition syndrome: a case report and review of literature. Biomark Res. 2015;3:14. https:\/\/doi.org\/10.1186\/s40364-015-0040-5","journal-title":"Biomark Res"},{"key":"1749_CR83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14735\/amko2019S118","volume":"32","author":"L Foretov\u00e1","year":"2019","unstructured":"Foretov\u00e1 L, Navr\u00e1tilov\u00e1 M, Svoboda M, H\u00e1zov\u00e1 J, Va\u0161\u00ed\u010dkov\u00e1 P, S\u0165ahlov\u00e1 EH, et al. BAP1 syndrome - predisposition to malignant mesothelioma, skin and uveal melanoma, renal and other cancers. Klin Onkol. 2019;32:118\u201322. https:\/\/doi.org\/10.14735\/amko2019S118","journal-title":"Klin Onkol"},{"key":"1749_CR84","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","volume":"153","author":"AM Haugh","year":"2017","unstructured":"Haugh AM, Njauw C-N, Bubley JA, Verz\u00ec AE, Zhang B, Kudalkar E, et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 2017;153:999\u20131006. https:\/\/doi.org\/10.1001\/jamadermatol.2017.2330","journal-title":"JAMA Dermatol"},{"key":"1749_CR85","doi-asserted-by":"publisher","unstructured":"Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other Germline Mutations. J Clin Oncol. 2018;JCO2018790352. https:\/\/doi.org\/10.1200\/JCO.2018.79.0352","DOI":"10.1200\/JCO.2018.79.0352"},{"key":"1749_CR86","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","volume":"110","author":"S Walpole","year":"2018","unstructured":"Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst. 2018;110:1328\u201341. https:\/\/doi.org\/10.1093\/jnci\/djy171","journal-title":"J Natl Cancer Inst"},{"key":"1749_CR87","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017;19:1447\u201356. https:\/\/doi.org\/10.1093\/neuonc\/nox094","journal-title":"Neuro Oncol"},{"key":"1749_CR88","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","volume":"30","author":"B Masoomian","year":"2018","unstructured":"Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30:102\u20139. https:\/\/doi.org\/10.1016\/j.joco.2018.02.005","journal-title":"J Curr Ophthalmol"},{"key":"1749_CR89","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s12885-018-5079-x","volume":"18","author":"KG Ewens","year":"2018","unstructured":"Ewens KG, Lalonde E, Richards-Yutz J, Shields CL, Ganguly A. Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma. BMC Cancer. 2018;18:1172. https:\/\/doi.org\/10.1186\/s12885-018-5079-x","journal-title":"BMC Cancer"},{"key":"1749_CR90","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10:565\u201376. https:\/\/doi.org\/10.1097\/JTO.0000000000000471","journal-title":"J Thorac Oncol"},{"key":"1749_CR91","doi-asserted-by":"publisher","unstructured":"Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, Kurzrock R. Genomic landscape of malignant mesotheliomas. Mol Cancer Ther. 2016;15:2498\u2013507. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0229","DOI":"10.1158\/1535-7163.MCT-16-0229"},{"key":"1749_CR92","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.7150\/jca.27281","volume":"9","author":"S Jin","year":"2018","unstructured":"Jin S, Wu J, Zhu Y, Gu W, Wan F, Xiao W, et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in Silico. J Cancer. 2018;9:4108\u201316. https:\/\/doi.org\/10.7150\/jca.27281","journal-title":"J Cancer"},{"key":"1749_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cancergen.2018.03.002","volume":"224\u2013225","author":"A Mosbeh","year":"2018","unstructured":"Mosbeh A, Halfawy K, Abdel-Mageed WS, Sweed D, Rahman MHA. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma. Cancer Genet. 2018;224\u2013225:21\u20138. https:\/\/doi.org\/10.1016\/j.cancergen.2018.03.002","journal-title":"Cancer Genet"},{"key":"1749_CR94","doi-asserted-by":"publisher","unstructured":"Chen Y-B, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016;7:13131. https:\/\/doi.org\/10.1038\/ncomms13131","DOI":"10.1038\/ncomms13131"},{"key":"1749_CR95","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","volume":"47","author":"M Farzin","year":"2015","unstructured":"Farzin M, Toon CW, Clarkson A, Sioson L, Watson N, Andrici J, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology. 2015;47:302\u20137. https:\/\/doi.org\/10.1097\/PAT.0000000000000250","journal-title":"Pathology"},{"key":"1749_CR96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/fon.14.198","volume":"11","author":"S Santhosh","year":"2015","unstructured":"Santhosh S, Kumar P, Ramprasad V, Chaudhuri A. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. Future Oncol. 2015;11:279\u201393. https:\/\/doi.org\/10.2217\/fon.14.198","journal-title":"Future Oncol"},{"key":"1749_CR97","doi-asserted-by":"publisher","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0946","DOI":"10.1158\/1078-0432.CCR-11-0946"},{"key":"1749_CR98","doi-asserted-by":"publisher","unstructured":"Sacco JJ, Kenyani J, Butt Z, Carter R, Chew HY, Cheeseman LP, et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget. 2015;6:13757\u201371. https:\/\/doi.org\/10.18632\/oncotarget.3765","DOI":"10.18632\/oncotarget.3765"},{"key":"1749_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25332-w","volume-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nature communications [Internet]","author":"LNHJJKSASF C A-E","year":"2021","unstructured":"L N, H J, J K, S A, S F, C A-EC A-E, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nature communications [Internet]. Nat Commun, 2021;12. https:\/\/doi.org\/10.1038\/s41467-021-25332-w"},{"key":"1749_CR100","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave LM, B\u00e9guelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344\u20139. https:\/\/doi.org\/10.1038\/nm.3947","journal-title":"Nat Med"},{"key":"1749_CR101","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.7150\/jca.26275","volume":"9","author":"C Sun","year":"2018","unstructured":"Sun C, Zhao C, Li S, Wang J, Zhou Q, Sun J, et al. EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis. J Cancer. 2018;9:3787\u201396. https:\/\/doi.org\/10.7150\/jca.26275","journal-title":"J Cancer"},{"key":"1749_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00277-7","volume-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. The Lancet Oncology [Internet]","author":"Z Mg","year":"2022","unstructured":"102. Mg Z, Pw S, S LM, S P, P T, D P, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. The Lancet Oncology [Internet]. Lancet Oncol; 2022 [cited 2025 Mar 1];23. https:\/\/doi.org\/10.1016\/S1470-2045(22)00277-7"},{"key":"1749_CR103","doi-asserted-by":"publisher","unstructured":"103. Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Sig Transduct Target Ther. Nature Publishing Group; 2023;8:1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01480-x","DOI":"10.1038\/s41392-023-01480-x"},{"key":"1749_CR104","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-023-02292-0","volume":"129","author":"F Zhong","year":"2023","unstructured":"Zhong F, Lin Y, Zhao L, Yang C, Ye Y, Shen Z. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. Br J Cancer. 2023;129:24\u201337. https:\/\/doi.org\/10.1038\/s41416-023-02292-0","journal-title":"Br J Cancer Nat Publishing Group"},{"key":"1749_CR105","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","volume":"28","author":"PA Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555\u201361. https:\/\/doi.org\/10.1200\/JCO.2009.27.5719","journal-title":"J Clin Oncol"},{"key":"1749_CR106","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","volume":"125","author":"RB Dann","year":"2012","unstructured":"Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, et al. BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125:677\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.006","journal-title":"Gynecol Oncol"},{"key":"1749_CR107","unstructured":"Muggia F, Safra T. BRCAness and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014;34:551\u20136."},{"key":"1749_CR108","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019;116:9008\u201313. https:\/\/doi.org\/10.1073\/pnas.1821510116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1749_CR109","doi-asserted-by":"publisher","unstructured":"109.Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. J Thorac Oncol. 2022;17:921\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2022.04.008","DOI":"10.1016\/j.jtho.2022.04.008"},{"key":"1749_CR110","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","volume":"27","author":"K Oehl","year":"2021","unstructured":"Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27:2277\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4037","journal-title":"Clin Cancer Res"},{"key":"1749_CR111","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.jtocrr.2021.100231","volume":"2","author":"A Ghafoor","year":"2021","unstructured":"Ghafoor A, Mian I, Wagner C, Mallory Y, Agra MG, Morrow B, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 Gene. JTO Clin Res Rep. 2021;2:100231. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100231","journal-title":"JTO Clin Res Rep"},{"key":"1749_CR112","doi-asserted-by":"publisher","first-page":"e2400406","DOI":"10.1200\/PO-24-00406","volume":"8","author":"TJ George","year":"2024","unstructured":"George TJ, Lee J-H, DeRemer DL, Hosein PJ, Staal S, Markham MJ, et al. Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms. JCO Precis Oncol. 2024;8:e2400406. https:\/\/doi.org\/10.1200\/PO-24-00406","journal-title":"JCO Precis Oncol"},{"key":"1749_CR113","doi-asserted-by":"publisher","unstructured":"113. Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9:593\u2013600. https:\/\/doi.org\/10.1016\/S2213-2600(20)30390-8","DOI":"10.1016\/S2213-2600(20)30390-8"},{"key":"1749_CR114","doi-asserted-by":"publisher","unstructured":"114. Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther. 2022;1\u201314. https:\/\/doi.org\/10.1080\/14712598.2022.2038132","DOI":"10.1080\/14712598.2022.2038132"},{"key":"1749_CR115","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"115.Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"key":"1749_CR116","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"1749_CR117","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","volume":"588","author":"C Kyi","year":"2014","unstructured":"Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368\u201376. https:\/\/doi.org\/10.1016\/j.febslet.2013.10.015","journal-title":"FEBS Lett"},{"key":"1749_CR118","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2174\/156800961506150805145120","volume":"15","author":"SC Azoury","year":"2015","unstructured":"Azoury SC, Straughan DM, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15:452\u201362. https:\/\/doi.org\/10.2174\/156800961506150805145120","journal-title":"Curr Cancer Drug Targets"},{"key":"1749_CR119","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44:1255\u201369. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.001","journal-title":"Immunity"},{"key":"1749_CR120","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc.2016.2","volume":"16","author":"NP Restifo","year":"2016","unstructured":"Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121\u20136. https:\/\/doi.org\/10.1038\/nrc.2016.2","journal-title":"Nat Rev Cancer"},{"key":"1749_CR121","doi-asserted-by":"publisher","unstructured":"Sabbatino F, Liguori L, Polcaro G, Salvato I, Caramori G, Salzano FA, et al. Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients. Int J Mol Sci. 2020;21:E7295. https:\/\/doi.org\/10.3390\/ijms21197295","DOI":"10.3390\/ijms21197295"},{"key":"1749_CR122","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.001","journal-title":"Cancer Treat Rev"},{"key":"1749_CR123","doi-asserted-by":"publisher","unstructured":"Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6:4. https:\/\/doi.org\/10.1186\/s40425-018-0314-1","DOI":"10.1186\/s40425-018-0314-1"},{"key":"1749_CR124","doi-asserted-by":"publisher","unstructured":"Sabbatino F, Marra A, Liguori L, Scognamiglio G, Fusciello C, Botti G, et al. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer. 2018;6:126. https:\/\/doi.org\/10.1186\/s40425-018-0439-2","DOI":"10.1186\/s40425-018-0439-2"},{"key":"1749_CR125","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1200\/EDBK_160766","volume":"35","author":"KR Spencer","year":"2016","unstructured":"Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book. 2016;35:e493\u2013503. https:\/\/doi.org\/10.1200\/EDBK_160766","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1749_CR126","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27:1910\u201320. https:\/\/doi.org\/10.1038\/s41591-021-01541-0","journal-title":"Nat Med"},{"key":"1749_CR127","doi-asserted-by":"publisher","unstructured":"Dudnik E, Bar J, Moore A, Gottfried T, Moskovitz M, Dudnik J, et al. BAP1-Altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-ribose) polymerase inhibitors. Front Oncol. 2021;11:603223. https:\/\/doi.org\/10.3389\/fonc.2021.603223","DOI":"10.3389\/fonc.2021.603223"},{"key":"1749_CR128","doi-asserted-by":"publisher","first-page":"e000228","DOI":"10.1136\/jitc-2019-000228","volume":"8","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Qi Y, Wang Z, Zeng H, Zhang H, Liu Z, et al. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. J Immunother Cancer. 2020;8:e000228. https:\/\/doi.org\/10.1136\/jitc-2019-000228","journal-title":"J Immunother Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01749-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:10:29Z","timestamp":1771600229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01749-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1749"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01749-8","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}